Skip to main content
SpringerLink
Log in

Immunopathophysiology of inflammatory bowel disease

  • Chapter
Immunological Aspects of Gastroenterology

Part of the book series: Immunology and Medicine Series ((IMME,volume 31))

  • 93 Accesses

Abstract

Crohn’s disease and ulcerative colitis are chronic inflammatory bowel diseases (IBD) of unknown aetiology. IBD is characterized by a chronic relapsing activity with healthy phases (“remission”) intervening with phases of inflammatory activity (“flare”). While some patients develop a chronically active disease in which inflammatory activity of different degrees is always present others go into complete clinical remission between active episodes. The immunological causes which are responsible for the different types of disease behaviour are unclear and the reasons for the development of relapses unknown. From epidemiological studies it appears likely that genetic causes exist which transfer the susceptibility for disease and also the type of disease (clinical course, anatomic localisation of inflammation).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Saverymuttu SH, Peters AM, Lavender JP, Pepys MB, Hodgson HJ, Chadwick VS. Quantitative fecal indium 111-labeled leucocyte excretion in the assessment of disease activity in Crohn’s disease. Gastroenterology 1983;85: 1333–1339.

    PubMed  CAS  Google Scholar 

  2. Saverymuttu SH, Peters AM, Lavender JP, Chadwick VS, Lavender JP. In vivo assessment of granulocyte migration to diseased bowel in Crohn’s disease. Gut. 1985;26:378–383.

    Article  PubMed  CAS  Google Scholar 

  3. Schoelmerich J, Schmidt E, Schumichen C, Billmann P, Schmidt H, Gerok W. Scintigraphic assessment of bowel involvement and disease activity in Crohn’s disease using technetium 99m hexamethyl propylene amine oxine as leukocyte label. Gastroenterology. 1988;95:1287–1293

    Google Scholar 

  4. Grisham MB, Granger DN. Neutrophil mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1998;33: 6S–15S

    Google Scholar 

  5. Faden H, Rossi TM. Chemiluminescent response of neutrophiles from patients with inflammatory bowel disease. Dig Dis Sci. 1985;30:139–142.

    Article  PubMed  CAS  Google Scholar 

  6. Anton PA, Targan SR, Shanahan F. Increased neutrophil receptors for and response to the pro-inflammatory bacterial peptide formyl-methionyl-leucylphenylalanine in Crohn’s disease. Gastroenterology. 1989;97:20–28.

    PubMed  CAS  Google Scholar 

  7. Kelleher D, Feighery C, Weir DG. Chemiluminescence by polymorphonuclear leucocyte subpopulations in chronic inflammatory bowel disease. Influence of the cell separation procedure. Digestion. 1990;45:158165.

    Google Scholar 

  8. Baldassano RN, Schreiber S, Johnston RB, Muraki T, MacDermott RP: Monocytes of patients with Crohn’s Disease are Primed for Accentuated Release of Toxic Oxygen Metabolites: Possible Role for Endotoxin. Gastroenterology 1993;105:60–66.

    PubMed  CAS  Google Scholar 

  9. Griga T, Tromm A, Schwegler U, May B. Enhanced superoxide anion release of normal neutrophil granulocytes primed with sera of patients with inactive inflammatory bowel disease. Z Gastroentrol 1995;33:345–348.

    CAS  Google Scholar 

  10. Andus T, Gross V, Caesar I, Krumm D, Hosp J, Gerok W, Scholmerich J. PMN-elastase in assessment of patients with inflammatory bowel disease. Dig Dis Sci 1993;38:1638–1644.

    Article  PubMed  CAS  Google Scholar 

  11. Adeyemi EO, Hodgson HJ. Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol. 1992;27:139–142.

    Article  PubMed  CAS  Google Scholar 

  12. Duchmann R, Kaiser I, Herrmann E, Mayet W, Ewe K, Meier zum Büschenfelde KH. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995; 102: 448–455.

    Article  PubMed  CAS  Google Scholar 

  13. Mahida YR, Wu K, Jewell DP. Enhanced production of interleukin 1-ß by mononuclear cells isolated from mucosa with active ulcerative colitis or Crohn’s disease. Gut 1989;30:835–838.

    Article  PubMed  CAS  Google Scholar 

  14. McAlindon M, Hawkey CJ & Mahida YR. Expression of interleukin-1 f3 and interleukin-1ß converting enzyme by macrophages in health and inflammatory bowel disease. Gut. 1998;42:214–219.

    Article  PubMed  CAS  Google Scholar 

  15. Brynskov J, Tvede N, Andersen CB, Vilien M: Increased concentrations of interleukin lß, interleukin 2, and soluble interleukin-2 receptors in endoscopic mucosal biopsy specimens with active inflammatory bowel disease. Gut 1992;33: 55–58.

    Article  PubMed  CAS  Google Scholar 

  16. Pullman WE, Elsbury S, Masanobu K, Hapel AJ, Doe WF. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1992;102:529–537.

    PubMed  CAS  Google Scholar 

  17. Nikolaus S, Bauditz J, Gionchetti P, Witt C, Lochs H, Schreiber S. Increased Secretion of Pro-Inflammatory Cytokines by Polymorphonuclear Neutrophils and Regulation by Interleukin 10 in Inflammatory Bowel Disease. Gut 1998;42:470–476.

    Article  PubMed  CAS  Google Scholar 

  18. Reinecker H-C, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol 1993;94:174–181.

    Article  PubMed  CAS  Google Scholar 

  19. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A, Antonioli D, Peppercorn MA, Strom TB (1992). Tumor necrosis factor-a, interleukin -lß and interleukin 6 expression in inflammatory bowel disease. Dig Dis Sci. 1992;37: 818–826.

    Article  PubMed  CAS  Google Scholar 

  20. Isaacs KL; Sartor RB; Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification. Gastroenterology. 1992;103:1587–1595.

    PubMed  CAS  Google Scholar 

  21. Woywodt A, Neustock P, Kruse A, Schwarting K, Ludwig D, Stange EF, Kirchner H. Cytokine expression in intestinal mucosal biopsies. In situ hybridisation of the mRNA for interleukin-1 beta, interleukin-6 and tumour necrosis factor-alpha in inflammatory bowel disease. Eur-Cytokine-Newt 1994;5:387–95.

    CAS  Google Scholar 

  22. Schreiber S, Nikolaus S, Hampe J, Hämling J, Koop I, Groessner B, Lochs H, Raedler A. Tumor Necrosis Factor-a and Interleukin 1ß in Relapse of Crohn’s Disease. The Lancet 1999;353: 459–461.

    Article  CAS  Google Scholar 

  23. Mahida Y R. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflammatory Bowel Diseases. 2000;6:21–33.

    Article  PubMed  CAS  Google Scholar 

  24. Kern JA, Lamb RJ, Reed JC, et al. Dexamethasone inhibition of interleukin1-beta production by human monocytes. J Clin Invest 1988;81:237–244.

    Article  PubMed  CAS  Google Scholar 

  25. Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G et al: Tumor-necrosis-factor antibody treatment in Crohn’s Disease. Lancet 1993; 342: 173–74.

    Article  PubMed  CAS  Google Scholar 

  26. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm MA. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet 1997; 22; 349: 521–52.

    Google Scholar 

  27. van Dullemen HM, van Deventer SJH, Hommes DW, Bij1 HA, Jansen J, Tytgat GNJ, Woody J: Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric antibody (cA2). Gastroenterology 1995; 109: 129–35

    Article  PubMed  Google Scholar 

  28. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, de Woody KL, Schaible TF, Rutgeerts PJ. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor ¡ªa for Crohn’s disease. New Engl J Med 1997; 337: 1029–1035.

    Article  PubMed  CAS  Google Scholar 

  29. D’haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 1999; 116: 1029–34

    Article  PubMed  Google Scholar 

  30. Bauditz J, Rückert Y, Raedler A, Nikolaus S, Lochs H, Schreiber S. Tumor necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn’s disease. Lancet 1995;345:1445.

    Article  PubMed  CAS  Google Scholar 

  31. Bauditz J, Hamling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumor necrosis factor inhibitor oxpentifylline does not improve steroid dependent chronic active Crohn’s disease in a pilot study. Gut 1997; 40: 470–475.

    PubMed  CAS  Google Scholar 

  32. Scallon BJ, Moore MA, Trinh DM, Ghrayeb J. Chimeric anti-TNF-a monoclonal antibody, cA2, binds recombinant transmembrane TNF-a and activates immune effector functions. Cytokine 1995; 7: 251–259.

    Google Scholar 

  33. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/Cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 1988; 53: 45–53.

    CAS  Google Scholar 

  34. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL; Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein. New Engl J Med 1997; 337: 141–147.

    Article  PubMed  CAS  Google Scholar 

  35. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–1110.

    Article  PubMed  CAS  Google Scholar 

  36. Neurath MF, Fuss I, Kelsall BL, Stuber E, Stober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182: 1281–1290.

    Article  PubMed  CAS  Google Scholar 

  37. Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde KH, Strober W, Kollias G. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997; 27: 1743–1750.

    Article  PubMed  CAS  Google Scholar 

  38. Gross V,. Andus T, Leser HG, Roth M, Schölmerich J. Inflammatory mediators in chronic inflammatory bowel disease. Klein Wochenschr 1991; 69: 981–987.

    Article  Google Scholar 

  39. Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn’s disease but not ulcerative colitis. Gastroenterology 1992; 102:1620–7.

    PubMed  CAS  Google Scholar 

  40. Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996; 157: 1261–1270.

    PubMed  CAS  Google Scholar 

  41. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, Pallone F. Interleukin 12 is expressed and actively released by Crohn’s disease lamina propria mononuclear cells. Gastroenterology 1997; 112: 1169–1178.

    Article  PubMed  CAS  Google Scholar 

  42. Christ AD, Stevens AC, Koeppen H, Walsh S, Omata F, Devergne O, Birkenbach M, Blumberg RS. An interleukin 12-related cytokine is up-regulated in ulcerative colitis but not in Crohn’s disease. Gastroenterology 1998; 115: 307–13

    Article  PubMed  CAS  Google Scholar 

  43. Bauditz J, Ortner M, Bierbaum M, Niedobitek M, Lochs H, Schreiber S. Human host defense against helicobacter pylori: role of pro-inflammatory cytokines IL-12, TNF-a, IL-1ß, IL-6 and IL-8. Gastroenterology 1997; 112: A67

    Google Scholar 

  44. Lieberman BY, Fiocchi C, Youngman KR, Sapatnekar WK, Proffitt MR. Interferon gamma production by human intestinal mucosa mononuclear cells. Decreased levels in inflammatory bowel disease. Dig Dis Sci 1988; 33: 1297–1304.

    Article  PubMed  CAS  Google Scholar 

  45. Essner R, Rhoades K, McBride WH, Morton DL, Esconomou JS. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol 1989; 142: 3857–3861.

    PubMed  CAS  Google Scholar 

  46. Donnelly RP, Fenton MJ, Finbloom DS, Gerrard TL. Differential regulation of IL-1 production in human monocytes by IFN-y and IL-4. J Immunol 1990; 145: 569–575.

    PubMed  CAS  Google Scholar 

  47. Vannier E, Miller LC, Dinarello CA. Coordinated antiinflammatory effects of interleukin 4: Interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proc Natl Acad Sci USA 1992; 89: 4076–4080.

    Article  PubMed  CAS  Google Scholar 

  48. Karttunnen R, Breese EJ, Walker-Smith JA, MacDonald TT. Decreased mucosal interleukin-4 production in gut inflammation. J Clin Pathol 1994; 47: 1015–1018.

    Article  PubMed  CAS  Google Scholar 

  49. West GA, Matsuura T, Levine AD, Klein JS, Fiocchi C. Interleukin 4 in inflammatory bowel and mucosal immune reactivity. Gastroenterology 1996;110:1683–1695.

    Article  PubMed  CAS  Google Scholar 

  50. Desreumaux P, Brandt E, Gambiez L, Emilie D, Geboes K, Klein O, Ectors N, Cortot A, Capron M, Colombel JF. Distinct cytokine patterns in early and chronic ileal lesions of Crohn’s disease. Gastroenterology 1997; 113: 118126.

    Google Scholar 

  51. Mosmann TR. Regulation of immune responses by T cells with different cytokine secretion profiles: Role of a new cytokine, cytokine synthesis inhibitory factor (IL-10). Int Arch Allergy Appl Immunol 1991; 94: 110115.

    Google Scholar 

  52. de Waal Malefyt R, Yssel H, Roncarolo M-G, Spits H, de Vries JE. Interleukin 10. Curr Opin Immunol 1992; 4: 314–322.

    Google Scholar 

  53. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991; 147: 3815–3822.

    PubMed  CAS  Google Scholar 

  54. Ralph P, Nakoinz I, Sampson-Johannes A, Fong S, Lowe D, Min H-Y, Lin L. IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992; 148: 808–814.

    PubMed  CAS  Google Scholar 

  55. Oswald IP, Gazzinelli RT, Sher A, James SL. IL-10 synergizes with IL-4 and transforming growth factor-ß to inhibit macrophage cytotoxic activity. J Immunol 1992; 148: 3578–3582.

    PubMed  CAS  Google Scholar 

  56. Fiorentino DF, Zlotnik A, Viera P, Mosmann TR, Howard M, Moore KW, O’Garra A. IL-10 acts on the antigen presenting cell to inhibit cytokine production by Thl cells. J Immunol 1991; 146: 3444–3451.

    PubMed  CAS  Google Scholar 

  57. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209–1220.

    Article  PubMed  Google Scholar 

  58. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cells. IV. Th2 clones secrete a factor that inhibits cytokine production by Thl clones. J Exp Med 1989; 170: 2081–2085.

    Article  PubMed  CAS  Google Scholar 

  59. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory Role of Interleukin 10 in Patients with Inflammatory Bowel Disease. Gastroenterology, 1995; 108: 1434–1444.

    Article  PubMed  CAS  Google Scholar 

  60. Seitz M, Loetscher P, Dewald B, Towbin H, Ceska M, Baggiolini M. Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins, and prostaglandin E by rheumatoid and osteoarthritic synoviocytesregulation by IFN-gamma and IL-4. J Immunol 1994; 152: 2060–2065.

    CAS  Google Scholar 

  61. Wirth JJ, Kierszenbaum F, Zlotnik A. Effects of IL-4 on macrophage functions: increased uptake and killing of a protozoan parasite (Trypanosoma cruzi). Immunology 1989; 66: 296–301.

    PubMed  CAS  Google Scholar 

  62. Powrie F, Leach MW, Mauze S, Menon S, Caddie LB, Coffmann RL (1994). Inhibition of TH1 responses prevents inflammatory bowel disease in SCID mice reconstituted with CD45RB(high) CD4 T cells. Immunity 1: 553–562.

    Article  PubMed  CAS  Google Scholar 

  63. Schreiber S, Heinig T, Panzer U, Reinking R, Bouchard A, Stahl PD et al: Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995; 108: 21–33

    Article  PubMed  CAS  Google Scholar 

  64. Kucharzik T, Lügering N, Weigelt H, Adolf M, Domschke W, Stoll R. Comparison of the suppressive effects of interleukin-13, interleukin-10, and interleukin-4 on blood monocytes from patients with IBD. Gastroenterology, 1996, 110: A943 (abstract).

    Article  Google Scholar 

  65. Fukushima K, West GA, Klein JS, Levine AD, Fiocchi C. Opposite modulatory activity of IL-10 and IL-4 on lamina propria mononuclear cells (LPMC) is stimulus-dependent. Gastroenterology 1993; 104: A702 (Abstr.).

    Google Scholar 

  66. Matsuura T, West GA, Klein JS, Levine AD, Kusugami K, Morise K, Fiocchi C. Immune activation gene products are resistent to IL-4 inhibitory activity in Crohn’s disease (CD). Gastroenterology 1993; 104: A739 (Abstr.).

    Google Scholar 

  67. Fedorak RN, Gang! A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B. Recombinant human interleukin-10 in the treatment of patients with mild to moderately active Crohn’s disease. Gastroenterology 2000;119:1473–82.

    Article  PubMed  CAS  Google Scholar 

  68. Schreiber S, Fedorak RN, Nielsen OH, Wild G, Williams NC, Jacyna M, Lashner BA, Gangl A, Isaacs K, van Deventer SJH, Koningsberger JC, Cohard M, Lebeaut A, Hanauer SB. Recombinant Human Interleukin-10 for the Treatment of Chronic Active Crohn’s Disease. Submitted.

    Google Scholar 

  69. Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1997; 1113, 383–389.

    Article  Google Scholar 

  70. Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell 1989; 58: 227–229.

    Article  PubMed  CAS  Google Scholar 

  71. Baldwin AS. The NF-KB and I-KB proteins: New discoveries and insights. Annu Rev Immunol 1996; 14, 649–681.

    Google Scholar 

  72. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of IkB-a proteolysis by site-specific signal induced phosporylation. Science 1995;267:1485–1487.

    Article  PubMed  CAS  Google Scholar 

  73. Schreiber S, Nikolaus S, Hampe J. Activation of Nuclear Factor kappa B in Inflammatory Bowel Disease. Gut 1998, 42: 477–485.

    Article  PubMed  CAS  Google Scholar 

  74. Neurath MF, Petterson S, Meyer zum Büschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-KB abrogates established experimental colitis in mice. Nature Medicine 1996; 2: 998–1004.

    Article  PubMed  CAS  Google Scholar 

  75. Malizia G; Calabrese A; Cottone M; Raimondo M; Trejdosiewicz LK; Smart CJ, Oliva L; Pagliaro L. Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology 1991;100:150–159.

    PubMed  CAS  Google Scholar 

  76. Koizumi M; King N; Lobb R; Benjamin C; Podolsky DK. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterology. 1992;103:840–7

    PubMed  CAS  Google Scholar 

  77. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994;8:504–512.

    Google Scholar 

  78. Jones SC, Banks RE, Haidar A, Gearing AJ, Hemingway IK, Ibbotson SH Dixon MF, Axon AT. Adhesion molecules in inflammatory bowel disease. Gut 1995;36:724–30.

    Article  PubMed  CAS  Google Scholar 

  79. Oshitani N, Campbell A, Bloom S, Kitano A, Kobayashi K, Jewell DP. Adhesion molecule expression on vascular endothelium and nitroblue tetrazolium reducing activity in human colonic mucosa. Scand J Gastroenterol 1995;30:915–20.

    Article  PubMed  CAS  Google Scholar 

  80. Patel RT, Pall AA, Adu D, Keighley MRB. Circulating soluble adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995;7:1037–1041.

    Article  PubMed  CAS  Google Scholar 

  81. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Tami JA, Bennett CF, Kisner DL, Shanahan WR Jr. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn’s disease. Gastroenterology 1998;114: 1133–42.

    Article  PubMed  CAS  Google Scholar 

  82. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sorensen IA, Binder V: Familial occurrence of inflammatory bowel disease. N Engl J Med 1991, 324: 84–8.

    Article  PubMed  CAS  Google Scholar 

  83. Orholm M, Munkholm P, Langholz E, Nielsen OH, et al.: Investigation of inheritance of chronic inflammatory bowel diseases by complex segregation analysis. BMJ 1993, 306: 20–4.

    Article  PubMed  CAS  Google Scholar 

  84. Kuster W, Pascoe L, Purrmann J, Funk S, Majewski F: The genetics of Crohn disease: complex segregation analysis of a family study with 265 patients with Crohn disease and 5,387 relatives. Am J Med Genet 1989, 32: 105–8.

    Article  PubMed  CAS  Google Scholar 

  85. Risch N: Linkage strategies for genetically complex traits. II. The power of affected relative pairs. Am J Hum Genet 1990, 46: 229–41.

    PubMed  CAS  Google Scholar 

  86. Hugot JP, Laurentpuig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, Naom I, Dupas JL, Vangossum A, Orholm M, et al.: Mapping of a susceptibility locus for Crohn’s disease on chromosome 16. Nature 1996, 379: 821–823.

    Article  PubMed  CAS  Google Scholar 

  87. Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, Welsh K, Terwilliger JD, Lathrop GM, Bell JI, Jewell DP: Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996, 14: 199–202.

    Google Scholar 

  88. Cho JH, Nicolae DL, Gold LH, Fields CT, LaBuda MC, Rohal PM, Pickles MR, Qin L, Fu Y, Mann JS, et al.: Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: Evidence for epistasis between 1 and IBD1. Proc Natl Acad Sci U S A. 1998; 95: 7502–7507.

    Article  PubMed  CAS  Google Scholar 

  89. Hampe J, Schreiber S, Shaw SH, Lau KF, Bridger S, MacPherson AJS, Cardon LR, Sakul H, Harris TJR, Buckler A, et al.: A genome-wide analysis provides evidence for novel linkages in Inflammatory Bowel Disease in a large European cohort. Am J Hum Genet 1999, 64: 808–816.

    Article  PubMed  CAS  Google Scholar 

  90. Hayward PA, Satsangi J, Jewell DP: Inflammatory bowel disease and the X chromosome. QJM 1996;89: 713–8.

    Article  PubMed  CAS  Google Scholar 

  91. Kruglyak L, Lander ES: Limits on fine mapping of complex traits. Am J Hum Genet 1996, 58: 1092–3.

    PubMed  CAS  Google Scholar 

  92. Hampe J, Wienker T, Nürnberg P, Schreiber S: Mapping genes for inflammatory bowel disease: implications of study design and population structure. Hum Hered. In press.

    Google Scholar 

  93. Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, Trent JM: Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A 1998, 95: 9979–84.

    Article  PubMed  CAS  Google Scholar 

  94. Lernmark A, Ott J: Sometimes it’s hot, sometimes it’s not. Nat Genet 1998, 19: 213–4.

    Article  PubMed  CAS  Google Scholar 

  95. Schreiber S, Hampe J. Genetics and Inflammatory Bowel Disease. Curr Opin Gastroen 1999;15:315–321.

    Article  CAS  Google Scholar 

  96. Risch N, Botstein D: A manic depressive history. Nat Genet 1996, 12: 351–3.

    Article  PubMed  CAS  Google Scholar 

  97. Schreiber S. Morbus Crohn und Colitis ulcerosa - Aspekte zur Pathophysiologie. Leber Magen Darm 1997;29(S3):34–39.

    Google Scholar 

Download references

Authors
  1. S. Schreiber
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Nottingham and Queen’s Medical Centre, Nottingham, UK

    Y. R. Mahida

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Kluwer Academic Publishers

About this chapter

Cite this chapter

Schreiber, S. (2001). Immunopathophysiology of inflammatory bowel disease. In: Mahida, Y.R. (eds) Immunological Aspects of Gastroenterology. Immunology and Medicine Series, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-0790-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-94-010-0790-0_9

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-3852-2

  • Online ISBN: 978-94-010-0790-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation